Global medical tech company BD faces reduced blood culture vial supply, impacting patient diagnosis and treatment.
BD, a global medical tech company, faces reduced availability of blood culture vials from its supplier, as stated in a U.S. FDA letter to healthcare providers. BD is addressing the issue with measures such as providing the supplier with manufacturing expertise, using air shipments, and collaborating with the FDA. The shortage may impact patient diagnosis, follow-up treatment, and antimicrobial management efforts.
July 10, 2024
5 Articles